Trials / Sponsors / NiKang Therapeutics, Inc.
NiKang Therapeutics, Inc.
Industry · 5 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors | Phase 1 | 2025-03-25 |
| Recruiting | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult | Phase 1 | 2024-09-19 |
| Terminated | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 | 2024-02-23 |
| Terminated | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccR ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer | Phase 2 | 2023-07-28 |
| Terminated | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer | Phase 1 / Phase 2 | 2021-10-26 |